摘要
目的:酮咯酸氨丁三醇用于乳腺癌患者术后静脉自控镇痛,观察其临床应用的效果。方法:选择需进行乳腺癌改良根治手术的患者共60例,年龄36～61岁,体重47～64 kg,ASAⅠ～Ⅱ级。随机分为两组,A组采用静脉泵注芬太尼术后镇痛,B组采用静脉泵注酮咯酸氨丁三醇术后镇痛。手术结束麻醉清醒后连接电子镇痛泵送入监护室,监测血压、心率、血氧饱和度等指标。观察术后2 h、4 h、8 h、12 h、24 h和48 h不同时点的镇痛镇静评分及不良反应等情况。结果:两组患者镇痛镇静评分差异无统计学意义(P>0.05),B组不良反应虽少于A组,但差异无统计学意义(P>0.05)。结论:酮咯酸氨丁三醇用于乳腺癌改良根治术后持续静脉镇痛安全有效。
Objective ： To observe the clinic effect and adverse reaction of ketorolac tromethamine used for patient controlled intravenous analgesia （PCIA） in breast cancer. Methods： 60 patients for operation on breast, ASA I - II , aged between 36 and 61, were randomly divided into two groups （Group A and Group B） and the fentanyl was used for PCIA in group A, the ketorolac tromethamine in group B. VAS and RSS scores of all the subjects were kept at different time points of 2 h, 4 h, 8 h, 12 h, 24 h and 48 h after operation with PCIA （maintenance dose 2 mL/h, PCA 0.5mL, interval time 15 mih）. Results： there was no sig- nificant difference between the two groups in VAS and RSS score （ P 〉 0.05 ） , and there was less adverse reaction in group B than in group A, but with no statistical difference （ P 〉 0.05 ）. Conclusion ： ketorolac tromethamine can be used for PCIA in breast cancer, safe and effective.
出处
《包头医学院学报》
CAS
2012年第4期51-53,共3页
Journal of Baotou Medical College
